Everolimus initiation and early calcineurin inhibitor withdrawal in heart transplant recipients: A randomized trial

American Journal of Transplantation

Volumn 14, Issue 8, 2014, Pages 1828-1838

  Andreassen, A K ^a   Andersson, B ^b   Gustafsson, F ^c   Eiskjaer H ^d   Gude, E ^a,e   Jansson, K ^f   Solbu, D ^g   Sigurdardottir, V ^b   Arora, S ^a   Dellgren, G ^b   Gullestad, L ^a,h  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c Rigshospitalet   (Denmark)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

^e LUND UNIVERSITY HOSPITAL   (Sweden)

^f LINKÖPING UNIVERSITY   (Sweden)

^g Medical Department   (Norway)

^h UNIVERSITY OF OSLO   (Norway)

Author keywords

Clinical research practice; heart transplantation cardiology; immunosuppressant; immunosuppression immune modulation; immunosuppressive regimens; mechanistic target of rapamycin: everolimus; minimization withdrawal

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; CORTICOSTEROID; CREATININE; CYCLOSPORIN; EVEROLIMUS; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; THYMOCYTE ANTIBODY; TROPONIN T; VALGANCICLOVIR; CALCINEURIN INHIBITOR; IMMUNOSUPPRESSIVE AGENT; MTOR PROTEIN, HUMAN; MYCOPHENOLIC ACID; RAPAMYCIN; TARGET OF RAPAMYCIN KINASE;

ACUTE GRAFT REJECTION; ADULT; AGED; APHTHOUS STOMATITIS; ARTERIAL WALL THICKNESS; ARTICLE; BACTERIAL INFECTION; CARDIAC ALLOGRAFT VASCULOPATHY; CARDIAC GRAFT REJECTION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS INFECTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EDEMA; FEMALE; GRAFT RECIPIENT; HEART GRAFT; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE BIOPSY; HUMAN; HUMAN TISSUE; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INTRAVASCULAR ULTRASOUND; KIDNEY FUNCTION; LEUKOPENIA; MACROALBUMINURIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; OUTCOME ASSESSMENT; PARALLEL DESIGN; PERICARDIAL EFFUSION; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SEPSIS; SIDE EFFECT; VIREMIA; WOUND COMPLICATION; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DRUG ADMINISTRATION; GLOMERULUS FILTRATION RATE; GRAFT REJECTION; HEART FAILURE; HEART TRANSPLANTATION; METABOLISM; MIDDLE AGED;

ADRENAL CORTEX HORMONES; ADULT; AGED; CALCINEURIN INHIBITORS; CYCLOSPORINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLOMERULAR FILTRATION RATE; GRAFT REJECTION; HEART FAILURE; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; SIROLIMUS; TOR SERINE-THREONINE KINASES; VENTRICULAR FUNCTION, LEFT;

EID: 84904705879     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12809     Document Type: Article

References (40)

1. Stehlik J, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: 29th official adult heart transplant report-2012. J Heart Lung Transplant 2012; 31: 1052-1064.
2. Dellgren G, Geiran O, Lemström K, et al. Three decades of heart transplantation in Scandinavia: Long-term follow-up. Eur J Heart Fail 2013; 15: 308-315.
3. Lindenfeld J, Miller GG, Shakar SF, et al. Drug therapy in the heart transplant recipient: Part II: Immunosuppressive drugs. Circulation 2004; 110: 3858-3865.
4. Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003; 349: 931-940.
5. Thomas HL, Banner NR, Murphy CL, et al. Incidence, determinants, and outcome of chronic kidney disease after adult heart transplantation in the United Kingdom. Transplantation 2012; 93: 1151-1157.
6. Bloom RD, Doyle AM., Kidney disease after heart and lung transplantation. Am J Transplant 2006; 6: 671-679.
7. Boilson BA, Raichlin E, Park SJ, Kushwaha SS., Device therapy and cardiac transplantation for end-stage heart failure. Curr Probl Cardiol 2010; 35: 8-64.
8. Merville P., Combating chronic renal allograft dysfunction: Optimal immunosuppressive regimens. Drugs 2005; 65: 615-631.
9. Schuler W, Sedrani R, Cottens S, et al. SDZ RAD, a new rapamycin derivative: Pharmacological properties in vitro and in vivo. Transplantation 1997; 64: 36-42.
10. Zuckermann AO, Aliabadi AZ., Calcineurin-inhibitor minimization protocols in heart transplantation. Transpl Int 2009; 22: 78-89.
11. Flechner SM, Kobashigawa J, Klintmalm G., Calcineurin inhibitor-sparing regimens in solid organ transplantation: Focus on improving renal function and nephrotoxicity. Clin Transplant 2008; 22: 1-15.
12. Gude E, Gullestad L, Arora S, et al. Benefit of early conversion from CNI-based to everolimus-based immunosuppression in heart transplantation. J Heart Lung Transplant 2010; 29: 641-647.
13. Eisen HJ, Kobashigawa J, Starling RC, et al. Everolimus versus mycophenolate mofetil in heart transplantation: A randomized, multicenter trial. Am J Transplant 2013; 13: 1203-1216.
14. González-Vílchez F, de Prada JA, Exposito V, et al. Avoidance of calcineurin inhibitors with use of proliferation signal inhibitors in de novo heart transplantation with renal failure. J Heart Lung Transplant 2008; 27: 1135-1141.
15. Hunt J, Bedanova H, Starling RC, et al. Premature ternmination of a prospective, open label, randomized, multicenter study to Srl to replace CNIs (CNI) in a standard care regimen of CNI, MMF and corticosteroids early after heart transplantation. J Heart Lung Transplant 2007; 26 (Suppl): S203.
16. World Medical Association Ethics Unit. Declaration of Helsinki 2007. Available at: http://www.wma.net./en/30publications/10policies/b3/index.html. Accessed June 30, 2014.
17. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D., A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Ann Intern Med 1999; 30: 461-470.
18. Stewart S, Winters GL, Fishbein MC, et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant 2005; 24: 1710-1720.
19. Mintz GS, Nissen SE, Anderson WD, et al. American College of Cardiology Clinical Expert Consensus Document on Standards for Acquisition, Measurement and Reporting of Intravascular Ultrasound Studies (IVUS). A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 2001; 37: 1478-1492.
20. Kobashigawa JA, Tobis JM, Starling RC, et al. Multicenter intravascular ultrasound validation study among heart transplant recipients: Outcomes after five years. J Am Coll Cardiol 2005; 45: 1532-1537.
21. Tuzcu EM, Kapadia SR, Sachar R, et al. Intravascular ultrasound evidence of angiographically silent progression in coronary atherosclerosis predicts long-term morbidity and mortality after cardiac transplantation. J Am Coll Cardiol 2005; 45: 1538-1542.
22. Gullestad L, Iversen M, Mortensen SA, et al. Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dysfunction: A multicenter, randomized trial. Transplantation 2010; 89: 864-872.
23. Zuckermann A, Wang SS, Ross H, et al. Efficacy and safety of low-dose cyclosporine with everolimus and steroids in de novo heart transplant patients: A multicentre, randomized trial. J Transplant 2011; 2011: 535983.
24. Gustafsson F, Ross HJ, Delgado MS, Bernabeo G, Delgado DH., Sirolimus-based immunosuppression after cardiac transplantation: Predictors of recovery from calcineurin inhibitor-induced renal dysfunction. J Heart Lung Transplant 2007; 26: 998-1003.
25. Letavernier E, Bruneval P, Vandermeersch S, et al. Sirolimus interacts with pathways essential for podocyte integrity. Nephrol Dial Transplant 2009; 24: 630-638.
26. Pattison JM, Petersen J, Kuo P, Valantine V, Robbins RC, Theodore J., The incidence of renal failure in one hundred consecutive heart-lung transplant recipients. Am J Kidney Dis 1995; 26: 643-648.
27. Myers BD, Ross J, Newton L, Luetscher J, Perlroth M., Cyclosporine-associated chronic nephropathy. N Engl J Med 1984; 311: 699-705.
28. Schönenberger E, Ehrich JH, Haller H, Sciffer M., The potocyte as a direct target of immunosuppressive agents. Nephrol Dial Transplant 2011; 26: 18-24.
29. Hillege HL, Girbes AR, de Kam PJ, et al. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation 2000; 102: 203-210.
30. Eisen HJ, Tuzcu EM, Dorent R, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003; 349: 847-858.
31. Dambrin C, Klupp J, Bîrsan T, et al. Sirolimus (rapamycin) monotherapy prevents graft vascular disease in nonhuman primate recipients of orthotopic aortic allografts. Circulation 2003; 107: 2369-2374.
32. Tuzcu EM, Hobbs RE, Rincon G, et al. Occult and frequent transmission of atherosclerotic coronary disease with cardiac transplantation. Insights from intravascular ultrasound. Circulation 1995; 91: 1706-1713.
33. Yamasaki M, Sakurai R, Hirohata A, et al. Impact of donor-transmitted atherosclerosis on early cardiac allograft vasculopathy: New findings by three-dimensional intravascular ultrasound analysis. Transplantation 2011; 91: 1406-1411.
34. Kobashigawa J, Ross H, Bara C, et al. Everolimus is associated with a reduced incidence of cytomegalovirus infection following de novo cardiac transplantation. Transpl Infect Dis 2013; 15: 150-162.
35. Hill JA, Hummel M, Starling RC, et al. A lower incidence of cytomegalovirus infection in de novo heart transplant recipients randomized to everolimus. Transplantation 2007; 84: 1436-1442.
36. Potena L, Valantine HA., Cytomegalovirus-associated allograft rejection in heart transplant patients. Curr Opin Infect Dis 2007; 20: 425-431.
37. Zuckermann A, Arizon JM, Dong G, et al. Impact of de novo everolimus-based immunosuppression on incisional complications in heart transplantation. Transplantation 2011; 92: 594-600.
38. Vincenti F, Charpentier B, Vanrenterghem Y, et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 2010; 10: 535-546.
39. Hertz MI., The Registry of the International Society for Heart and Lung Transplantation-Introduction to the 2012 annual reports: New leadership, same vision. J Heart Lung Transplant 2012; 31: 1045-1051.
40. Egstrup M, Schou M, Gustafsson I, Kistorp CN, Hildebrandt PR, Tuxen CD., Oral glucose tolerance testing in an outpatient heart failure clinic reveals a high proportion of undiagnosed diabetic patients with an adverse prognosis. Eur J Heart Fail 2011; 13: 319-326.